BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25218345)

  • 1. B cell CLL/lymphoma 6 member B inhibits hepatocellular carcinoma metastases in vitro and in mice.
    Wang J; Dong L; Xu L; Chu ES; Chen Y; Shen J; Li X; Wong CC; Sung JJ; Yu J
    Cancer Lett; 2014 Dec; 355(2):192-200. PubMed ID: 25218345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival.
    Xu L; Li X; Chu ES; Zhao G; Go MY; Tao Q; Jin H; Zeng Z; Sung JJ; Yu J
    Gut; 2012 Jul; 61(7):977-85. PubMed ID: 21917650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
    Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
    Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo.
    Bai Y; Wang J; Han J; Xie XL; Ji CG; Yin J; Chen L; Wang CK; Jiang XY; Qi W; Jiang HQ
    Mol Carcinog; 2017 Mar; 56(3):1137-1149. PubMed ID: 27770580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL6B expression in hepatocellular carcinoma and its efficacy in the inhibition of liver damage and fibrogenesis.
    Wang W; Huang P; Wu P; Kong R; Xu J; Zhang L; Yang Q; Xie Q; Zhang L; Zhou X; Chen L; Xie H; Zhou L; Zheng S
    Oncotarget; 2015 Aug; 6(24):20252-65. PubMed ID: 25970780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
    Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
    Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray.
    Li Y; Tang Y; Ye L; Liu B; Liu K; Chen J; Xue Q
    J Cancer Res Clin Oncol; 2003 Jan; 129(1):43-51. PubMed ID: 12618900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDA-7/IL-24 suppresses tumor adhesion and invasive potential in hepatocellular carcinoma cell lines.
    Huo W; Li ZM; Zhu XM; Bao YM; An LJ
    Oncol Rep; 2013 Aug; 30(2):986-92. PubMed ID: 23722307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.
    Zhao R; Wang N; Huang H; Ma W; Yan Q
    Liver Int; 2014 Jul; 34(6):e151-60. PubMed ID: 24529164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfatide epigenetically regulates miR-223 and promotes the migration of human hepatocellular carcinoma cells.
    Dong YW; Wang R; Cai QQ; Qi B; Wu W; Zhang YH; Wu XZ
    J Hepatol; 2014 Apr; 60(4):792-801. PubMed ID: 24333181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma.
    He F; Li J; Xu J; Zhang S; Xu Y; Zhao W; Yin Z; Wang X
    J Exp Clin Cancer Res; 2015 May; 34(1):47. PubMed ID: 25975202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CtBP1 is involved in epithelial-mesenchymal transition and is a potential therapeutic target for hepatocellular carcinoma.
    Zhang XL; Huang CX; Zhang J; Inoue A; Zeng SE; Xiao SJ
    Oncol Rep; 2013 Aug; 30(2):809-14. PubMed ID: 23756565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma.
    Sheng SL; Liu JJ; Dai YH; Sun XG; Xiong XP; Huang G
    FEBS J; 2012 Oct; 279(20):3898-910. PubMed ID: 22897481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma.
    Yan Q; Zhang ZF; Chen XP; Gutmann DH; Xiong M; Xiao ZY; Huang ZY
    Int J Oncol; 2008 May; 32(5):1057-63. PubMed ID: 18425332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and inhibitory role of TIMP-3 in hepatocellular carcinoma.
    Shen B; Jiang Y; Chen YR; Zheng HC; Zeng W; Li YY; Yin A; Nie Y
    Oncol Rep; 2016 Jul; 36(1):494-502. PubMed ID: 27222429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.
    Zhao J; Lu B; Xu H; Tong X; Wu G; Zhang X; Liang A; Cong W; Dai J; Wang H; Wu M; Guo Y
    Hepatology; 2008 Jul; 48(1):265-75. PubMed ID: 18537194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tiam1 is associated with hepatocellular carcinoma metastasis.
    Huang J; Ye X; Guan J; Chen B; Li Q; Zheng X; Liu L; Wang S; Ding Y; Ding Y; Chen L
    Int J Cancer; 2013 Jan; 132(1):90-100. PubMed ID: 22573407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3'3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling.
    Li WX; Chen LP; Sun MY; Li JT; Liu HZ; Zhu W
    Oncotarget; 2015 Sep; 6(27):23776-92. PubMed ID: 26068982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIP30 mutant derived from hepatocellular carcinoma specimens promotes growth of HepG2 cells through up-regulation of N-cadherin.
    Jiang C; Pecha J; Hoshino I; Ankrapp D; Xiao H
    Cancer Res; 2007 Apr; 67(8):3574-82. PubMed ID: 17440068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of T-cell lymphoma invasion and metastasis 2 (TIAM2) promotes proliferation and invasion of liver cancer.
    Chen JS; Su IJ; Leu YW; Young KC; Sun HS
    Int J Cancer; 2012 Mar; 130(6):1302-13. PubMed ID: 21469146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.